Part 2: Performance Reporting2.3 Performance by Outcome
Part 3: Management ArrangementsPart 4: Accountability ReportingPart 6: Contact DetailsAppendicesYou are in:
Access to cost-effective medicines, including through the Pharmaceutical Benefits Scheme and related subsidies, and assistance for medication management through industry partnerships.
Source: Medicare Australia pharmacy approval data 30 June 2010; Census 2006; PhARIA 2008-09*
Other locations – Christmas Island, Cocos (Keeling) Islands and Jervis Bay
| Fourth Community Pharmacy Agreement | |
|---|---|
| Qualitative Deliverable: | Regular stakeholder participation in program development and implementation: Programs under the Fourth Agreement are overseen by the Professional Programs and Services Advisory Committee and its steering committees. Membership includes pharmacists, pharmacy owners, consumers, Indigenous organisations, relevant peak bodies and academics. |
| Result: Deliverable met. | |
| Consultation with stakeholders through their representation on the Professional Programs and Services Advisory Committee and its steering committees has been a regular part of program development and management under the Fourth Community Pharmacy Agreement. In 2009-10, the committee oversaw the implementation of three new programs, including the Hepatitis C Public Health Promotion Pilot Program. In addition to representation from peak stakeholder groups through the Hepatitis C Steering Committee, implementation of the program included engagement with the Australian Society for HIV Medicine, the Australian Injecting and Illicit Drug Users’ League and the Australian Hepatitis Council. Consultation with stakeholders was also undertaken in 2009-10 on programs that had been established in prior years. For example, consumers, general practitioners and hospital pharmacists were approached on ways to improve the effectiveness of the Home Medicines Review Program, including targeting the reviews to patients who would benefit most. The Fifth Community Pharmacy Agreement broadens opportunities for stakeholder participation in program development through the Programs Reference Group, which will include representatives from peak stakeholder groups. |
|
| Improved Use of Medicines through Awareness | |
| Qualitative Deliverable: | Regular stakeholder participation in program development and implementation: Enhancements to the National Prescribing Service program recognise input from the service’s 45 member organisations and information gathered through stakeholder workshops. |
| Result: Deliverable met. | |
| Stakeholder participation is integral to the work of the National Prescribing Service. The service’s 45 member organisations include doctors, pharmacists and other health professionals and consumers, and contribute to the development and delivery of the service’s strategies and programs. The service consulted members and stakeholders through its annual Members’ Planning Days, stakeholder reference groups, regular communications and surveys. |
|
| Quantitative Deliverable: | Percentage of variance between actual and budgeted expenses. | ||
| 2009-10 Target: | ≤0.5% | 2009-10 Actual: | 4.3% |
| Result: Deliverable not met. | |||
| Several large demand driven activities are administered under Program 2.1, some of which have parameters that change throughout the year. | |||
| Fourth Community Pharmacy Agreement | |||
|---|---|---|---|
| Quantitative Deliverable: | Proportion of community pharmacies participating in programs to assist patients in managing their medicines. | ||
| 2009-10 Target: | 60% | 2009-10 Actual: | 70% |
| Result: Deliverable met. | |||
| Pharmacy participation in programs that assisted patients in managing their medicines was higher in 2009-10. For example, more than 70 per cent (3,676) of eligible community pharmacies registered to participate in phase two of the Dose Administrations Aids program, which was a significant increase from the 50 per cent (2,460) of eligible community pharmacies that completed phase one. The increased participation rate indicates that more patients could access a service to help them to better manage their medications and therefore reduces the risk of a medicine related adverse event occurring. In addition, the number of providers registered to participate in the Home Medicines Review Program (community pharmacies) at June 2010 was 4,362 (around 83 per cent of community pharmacies). This means that patients have good access to medicine review services should they be identified by their general practitioner as being in need of a review. |
|||
| Quantitative Deliverable: | Number of pharmacists accredited to provide medication reviews. | ||
| 2009-10 Target: | 1,790 | 2009-10 Actual: | 1,900 |
| Result: Deliverable met. | |||
| As at 22 June 2010, more than 1,900 pharmacists were accredited to undertake medication reviews. | |||
| Improved Use of Medicines through Awareness | |||
| Quantitative Deliverable: | Number of therapeutic topics in NPS News provided to doctors and pharmacists. | ||
| 2009-10 Target: | 5 | 2009-10 Actual: | 6 |
| Result: Deliverable met. | |||
| The National Prescribing Service has provided independent, evidence-based information on therapeutic topics through publication of the NPS News, which is supplied to doctors and pharmacists. This year’s topics of focus were: antidepressant use, hypnotic drugs, smoking cessation, treatments in menopause, the use of analgesics and urinary incontinence. | |||
| Fourth Community Pharmacy Agreement | |
|---|---|
| Qualitative Indicator: | The impact of the Fourth Agreement will be measured by the services provided by community pharmacies, the extent to which they improve access to quality community pharmacy services, and the extent of community pharmacy participation in new programs. Each new program under the Fourth Agreement is being conducted as a trial to determine how the services should be provided to meet the needs of patients and which patients will most benefit from the service. This information is being obtained from comprehensive evaluations of the programs, which will be completed in 2009-10. |
| Result: Indicator met. | |
| The department implemented three new programs in 2009-10. The Pandemic Influenza Preparedness Program assisted up to 2,500 community pharmacies in the development of a business continuity plan to help them maintain services to the community during a pandemic. The program provided education and training in basic infection control measures and the use of personal protective equipment to enable pharmacy staff to stay at work during a pandemic. The Practice Change Program also began in 2009-10. The program encouraged community pharmacies to embed programs and services under the Fourth Community Pharmacy Agreement as part of their core business. More than 2,000 pharmacies enrolled. This program is also likely to result in improved uptake of the programs to be delivered under the Fifth Community Pharmacy Agreement. In 2009-10, the department evaluated 19 Fourth Community Pharmacy Agreement programs. The results of these evaluations will inform the development of new programs under the Fifth Community Pharmacy Agreement as well as improve existing programs. |
|
| Qualitative Indicator: | Several broader reviews being conducted under the Fourth Agreement are investigating issues impacting on community pharmacy. The reviews will be completed in 2009-10. |
| Result: Indicator met. | |
| The department completed five strategic policy reviews examining complex issues significantly impacting on community pharmacy as required under the Fourth Agreement, including the review into the staged supply of PBS medicines by a pharmacy when requested by a prescriber to do so for patients who are unable to manage the full quantity of their medications safely. All reviews agreed with the Pharmacy Guild of Australia were completed during the term of the Fourth Community Pharmacy Agreement. The findings of many of these reviews relate primarily to improving current systems, reducing the administrative burden on pharmacies in providing specific services, and providing funding for the provision of the service to support better health outcomes for patients. Several new programs under the Fifth Agreement address the findings of the reviews, including the introduction of the Staged Supply Allowance for pharmacies that comply with a set of quality standards in the provision of this service. |
|
| Fourth Community Pharmacy Agreement | |||
|---|---|---|---|
| Quantitative Indicator: | Number of evaluations of new and continuing programs completed. | ||
| 2009-10 Target: | 11 | 2009-10 Actual: | 13 |
| Result: Indicator met. | |||
| The department completed 13 evaluations covering 19 Fourth Community Pharmacy Agreement programs. Preliminary findings were considered during the development of the Fifth Community Pharmacy Agreement. Findings will inform the operating arrangements for continuing programs and the development of new Fifth Community Pharmacy Agreement programs. | |||
| Quantitative Indicator: | Number of reviews of issues impacting on community pharmacy completed. | ||
| 2009-10 Target: | 4 | 2009-10 Actual: | 5 |
| Result: Indicator met. | |||
| The department completed five reviews of complex issues impacting on community pharmacy during 2009-10. All reviews agreed with the Pharmacy Guild of Australia were completed during the term of the Fourth Community Pharmacy Agreement. | |||
| Quantitative Indicator: | Proportion of urban and regional Aboriginal Community Controlled Health Organisations participating in the Quality Use of Medicines Maximised for Aboriginal and Torres Strait Islander Peoples program. | ||
| 2009-10 Target: | 94% | 2009-10 Actual: | 98% |
| Result: Indicator met. | |||
| Ninety-eight per cent of urban and regional Aboriginal Community Controlled Health Organisations participated in the Quality Use of Medicines Maximised for Aboriginal and Torres Strait Islander Peoples program. This compares with 94 per cent in 2008-09. | |||
| Improved Use of Medicines Through Awareness | |||
| Quantitative Indicator: | Number of general doctors participating in education initiatives. | ||
| 2009-10 Target: | 12,500 | 2009-10 Actual: | 12,727 |
| Result: Indicator met. | |||
| A major focus of the National Prescribing Service is providing educational activities to health professionals. In 2009-10, 12,727 general practitioners participated in at least one education initiative, in comparison to the 12,699 participants in 2008-09. | |||
| Qualitative Deliverable:1 | Regular stakeholder participation in program development: The Department of Health and Ageing and the Pharmaceutical Benefits Advisory Committee have undertaken regular and structured meetings to facilitate ongoing dialogue and consultation with industry, consumers, professional associations and other stakeholders. The Pharmaceutical Benefits Advisory Committee agenda is now made publicly available six weeks before each meeting. The public is encouraged to make comments on the medicines before being considered for subsidy especially in relation to living with the condition that the medicine treats. The Access to Medicines Working Group will continue to liaise with the Pharmaceutical Benefits Advisory Committee to evaluate the benefits of this initiative. The National Medicines Policy advisory structure provides an opportunity for all National Medicines Policy partners, including the chairs of related organisations/ committees, Australian Government representatives, individual experts and stakeholder groups to contribute to implementation of Australia’s National Medicines Policy. |
| Result: Deliverable met. | |
| Regular meetings, both formal (such as the Access to Medicines Working Group and the Pharmaceutical Industry Working Group) and informal, have provided industry with an opportunity to engage in open and ongoing dialogue about medicines and industry issues, such as the uptake of generic medicines. In 2009-10, the Access to Medicines Working Group undertook pilots for the early and extended evaluation of complex Pharmaceutical Benefits Advisory Committee submissions, and for enhanced pre-Pharmaceutical Benefits Advisory Committee submission meetings. The Access to Medicines Working Group also worked to provide greater clarity and transparency about the evidence expected of pharmaceutical companies by the Pharmaceutical Benefits Advisory Committee and continued to evaluate the impact of the Pharmaceutical Benefits Advisory Committee guidelines. An evaluation of the generic consumer medicines campaign was also concluded in July 2009. The report found that the campaign had delivered a five per cent increase (72-77 per cent) in the number of consumers who felt confident in using generics and that 89 per cent of media coverage was favourable towards generic medicines. Based on this, a further $10 million will be provided to the National Prescribing Service to conduct another campaign in 2010-11. A formal assessment of the benefits of consumer input to the Pharmaceutical Benefits Advisory Committee process will be undertaken by the Access to Medicines Working Group in 2010-11. However, discussions held with peak health consumer organisations indicate that there may be a general lack of understanding of the committee’s approval process, the type of information consumers could provide and the impact of consumer input on the consideration process. Consequently, a project to prepare answers to Frequently Asked Questions based on consumer inquiries has begun. The project will also focus on the type of information consumers can provide to the committee, ways in which consumers can provide input, and how the committee will use this information. A consultation process to finalise this information for publication on the consumer sub-site of the PBS website www.pbs.gov.au will begin shortly. The consumer sub-site has been redesigned to prominently feature links to the committee agenda and the consumer input form. Consumer education sessions will be provided to further promote this initiative. Regular reports are being provided to the Access to Medicines Working Group on these developments. |
|
| Qualitative Deliverable: | New listings on the PBS must be clinically effective and cost-effective. In 2008-09, the Pharmaceutical Benefits Advisory Committee considered 213 submissions, of which 78 were major submissions requiring cost-effectiveness analysis, and 135 were minor submissions which did not require a cost-effectiveness analysis. |
| Result: Deliverable met. | |
| The Pharmaceutical Benefits Advisory Committee, when considering the listing of a new medicine on the PBS, must take into account the requirements of the National Health Act 1953, that the treatment be clinically effective, and cost-effective. Medicines considered in minor submissions are considered on a cost minimisation basis against existing PBS listed medicines. In 2009-10, the Pharmaceutical Benefits Advisory Committee considered 216 submissions, of which 73 were major submissions requiring cost-effectiveness analysis, and 143 were minor submissions which did not require a cost-effectiveness analysis. |
|
| Qualitative Deliverable: | After a positive recommendation by the Pharmaceutical Benefits Advisory Committee, listing a medicine occurs after completion of other processes including price negotiations with the sponsor, finalisation of the conditions for listing, quality and availability checks and consideration by the Australian Government. |
| Result: Deliverable met. | |
| In 2009-10, 119 new medicines were listed on the PBS after consideration by the Pharmaceutical Benefits Advisory Committee against appropriate criteria such as quality, availability and price. | |
1 Deliverable changed from 2009-10 Portfolio Budget Statements for factual accuracy.
| Quantitative Deliverable: | Percentage of variance between actual and budgeted expenses. | ||
| 2009-10 Target: | ≤0.5% | 2009-10 Actual: | -1.7% |
| Result: Deliverable not met. | |||
| Several large demand driven activities are administered under Program 2.2, some of which have parameters that change throughout the year. | |||
| Pharmaceuticals Benefits Scheme | |||
|---|---|---|---|
| Quantitative Deliverable: | Percentage of submissions in the PBAC for PBS listings that are considered within 17 weeks of lodgement. | ||
| 2009-10 Target: | 100% | 2009-10 Actual: | 100% |
| Result: Deliverable met. | |||
| In 2009-10, all submissions lodged with the secretariat of the Pharmaceutical Benefits Advisory Committee, on or before the advertised cut-off date, were considered by the committee at its next scheduled meeting, within 17 weeks of lodgement. | |||
| Qualitative Indicator: | Achieve better value from medicines that are subject to price competition by applying statutory price reductions to medicines in Formulary 2 by 1 August 2009. |
| Result: Indicator met. | |
| Under PBS Reform, implemented on 1 August 2007, more than 1,100 brands of medicines in Formulary 2A had their reimbursed price to pharmacist reduced by two per cent on 1 August 2009. These price reductions provide Australians with continued access to new and high cost medicines, while ensuring the PBS remains affordable into the future. |
|
| Qualitative Indicator: | Achieve better consumer participation in the consideration of PBAC submissions. Seventy-eight submissions were received from consumers for medicines considered at the November 2008 PBAC meeting. Fifty-eight submissions were received from consumers for medicines considered at the March 2009 PBAC meeting. The number of submissions received from consumers is expected to fluctuate according to the number of submissions being considered by the PBAC and the actual medicine being considered. |
| Result: Indicator met. | |
| In 2009-10, there were 187 consumer submissions on matters before the Pharmaceutical Benefits Advisory Committee, which was higher than the 136 received in 2008-09. Consumer submissions on medicines under consideration by the Pharmaceutical Benefits Advisory Committee, are provided to the medicine’s sponsor and are taken into account by the committee in its decision making process. In addition, the Consumer Health Forum, at the request of the Pharmaceutical Benefits Advisory Committee, also prepares consumer health impact statements. This information is used to assist the committee and sponsors understand the effect the availability of medicines has on patients. In 2009-10, the Consumer Health Forum prepared a consumer health impact statement on intermittent claudication, a condition caused by peripheral arterial disease. During the year, the department also organised a half-day session with peak consumer groups to map out strategies to facilitate greater consumer engagement. As a first step, the department is developing Frequently Asked Questions for publication on the consumer sub-site of the Pharmaceutical Benefits Scheme website2 and is redesigning the consumer pages to give greater access. |
|
| Pharmaceutical Benefits Scheme | |||
|---|---|---|---|
| Quantitative Indicator: | The proportion of prescriptions listed on the Schedule of Pharmaceutical Benefits subsidised on the Pharmaceutical Benefits Scheme. | ||
| 2009-10 Target: | 80% | 2009-10 Actual: | 80% |
| Result: Indicator met. | |||
| The estimate for the proportion of subsidised prescriptions listed on the Schedule of Pharmaceutical Benefits was 80 per cent for the period 1 July 2009 to 30 March 2010. The remaining 20 per cent of prescriptions were priced at or under the co-payment level (currently $33.30) and dispensed to general, non-safety net patients.3 | |||
2 Accessible at www.pbs.gov.au.
3 Information on the number of non-subsidised prescriptions supplied, that is, those under the patient co-payment amount, is generally not available. Information from a sample of pharmacies is only available after the end of a reporting period. This is due to the nature of the survey used as a source of data, and the length of time pharmacies take to submit prescriptions. The latest prescription supply data available for 2009-10 reporting year is to end of March 2010.
| Access to New and Existing Medicines | |
|---|---|
| Qualitative Deliverable: | More efficient and streamlined processes are used in the administration of the Life Saving Drugs Program. |
| Result: Deliverable met. | |
| The department introduced streamlined ordering and stock allocation processes to improve efficiency in the Life Saving Drugs Program. The department also developed clear requirements to monitor patients’ responses to therapy and to measure patients against the drug continuation criteria and disseminated revised program funding criteria and conditions. The department also developed new patient and doctor consent forms, for treatment under the program, and audited existing consent forms. | |
| Quantitative Deliverable: | Percentage of variance between actual and budgeted expenses. | ||
| 2009-10 Target: | ≤0.5% | 2009-10 Actual: | 4.4% |
| Result: Deliverable not met. | |||
| Several large demand driven activities are administered under Program 2.3, some of which have parameters that change throughout the year. | |||
| Access to New and Existing Medicines | |||
|---|---|---|---|
| Quantitative Deliverable: | Approximate number of patients assisted through the Life Saving Drugs Program. | ||
| 2009-10 Target: | 173 | 2009-10 Actual: | 159 |
| Result: Deliverable substantially met. | |||
| The department provided assistance to 159 patients through the Life Saving Drugs Program. All eligible patients that met the criteria for access to the program were assisted in 2009-10. The lower than forecast number is a result of this being a demand-driven program. Several large demand driven activities are administered under Program 2.3, some of which have parameters that change throughout the year. | |||
| Quantitative Deliverable: | Number of patients assisted through the Herceptin® Program. | ||
| 2009-10 Target: | 1,000 | 2009-10 Actual: | 1,093 |
| Result: Deliverable met. | |||
| During 2009–10, 449 new patients accessed the Herceptin® program. At 30 June 2010, 1,093 patients were active on the Herceptin® program, compared with 1,052 patients at 30 June 2009. Active patients are those patients currently receiving treatment on the program. | |||
| Access to New and Existing Medicines | |
|---|---|
| Qualitative Indicator: | The establishment, collection and monitoring of performance data under the Life Saving Drugs Program. |
| Result: Indicator met. | |
| The department collected data through a combination of international data registries, internal records, and through liaison and collaboration with treating doctors. Data collected was used by the clinical advisory committees to monitor patient response to treatment under the program. | |
| Qualitative Indicator: | Evaluations and reviews of Program 2.3: Targeted Assistance – Pharmaceuticals. |
| Result: Indicator met. | |
| In 2009, a review of the Life Saving Drugs Program was completed. As a result of the review, the Government made a number of decisions on how the program should continue to operate. In 2009-10, the department consulted with stakeholders on the outcomes of the review and the Government’s decisions. The department has begun implementing these decisions, including revising the funding criteria and patient conditions for the Life Saving Drugs Program, and commissioning a review by the Pharmaceutical Benefits Advisory Committee of the available international evidence of the relative clinical efficacy of Fabrazyme® and Replagal®. | |
| Access to New and Existing Medicines | |||
|---|---|---|---|
| Quantitative Indicator: | Eligible patients with access to fully subsidised medicines under the Life Saving Drugs Program. |
||
| 2009-10 Target: | 100% | 2009-10 Actual: | 100% |
| Result: Indicator met. | |||
| The department provided fully subsidised medicines to eligible patients. However, due to shortages of Fabrazyme® and Cerezyme®, the dose for some patients was reduced. This was managed in consultation with relevant clinical advisory committees and the doctors of affected patients. Trend data cannot be provided for this indicator as it was new in 2009-10. |
|||
| Stoma Appliance Scheme | |
|---|---|
| Qualitative Deliverable: | Through the review of products on the Stoma Appliance Scheme in 2009-10, increased downward pricing pressure on the scheme will lead to a more efficient and cost-effective program. |
| Result: Deliverable met. | |
| The department engaged an independent consultant to review products on the scheme. The department commenced consideration of the final report in June 2010. The report outlines ways in which the scheme’s sustainability could be improved. The department also made a number of administrative changes during 2009-10, including clarifying eligibility requirements to improve the scheme’s efficiency. | |
| Quantitative Deliverable: | Percentage of variance between actual and budgeted expenses. | ||
| 2009-10 Target: | ≤0.5% | 2009-10 Actual: | -1.3% |
| Result: Deliverable not met. | |||
| Several large demand driven activities are administered under Program 2.4, some of which have parameters that change throughout the year. | |||
| Quantitative Deliverable: | Average amount of Australian Government expenditure on Epidermolysis Bullosa dressings per patient who accesses the program (funding commenced January 2010). | ||
| 2009-10 Target: | $14,000 (6 months) | 2009-10 Actual: | $19,702 (6 months) |
| Result: Deliverable substantially met. | |||
| The department provided assistance to all eligible people under the National Epidermolysis Bullosa Dressing Scheme. The average expenditure per person for the last six months of 2009-10 was $19,702. The average cost of treating patients was higher than anticipated. Different patients have different levels of severity requiring different volumes and types of dressings. Levels of funding to the patient are not capped as this is a demand driven treatment to ensure patients have the best health outcome. The department receives a quarterly report that monitors dressing volumes and expenditure. | |||
| Epidermolysis Bullosa Dressing Scheme | |||
|---|---|---|---|
| Quantitative Indicator: | Approximate number of persons with Epidermolysis Bullosa benefiting from access to subsidised dressings through the dressing scheme. | ||
| 2009-10 Target: | 98 | 2009-10 Actual: | 43 |
| Result: Indicator substantially met. | |||
| In 2009-10, 43 people were being assisted under the National Epidermolysis Bullosa Dressing Scheme. While this number is less than anticipated, the number of new applications is increasing and participation is expected to improve as awareness of the program increases. A review of the program will be conducted 18 months after implementation of the program. Trend data is not available for this indicator as the Epidermolysis Bullosa program commenced in 2009-10. |
|||
| Stoma Appliance Scheme | |||
| Quantitative Indicator: | Approximate number of people who receive stoma-related products. | ||
| 2009-10 Target: | 37,750 | 2009-10 Actual: | 37,808 |
| Result: Indicator met. | |||
| The Stoma Appliance Scheme is a demand driven program and the number of people assisted can vary throughout the year. Trend data is not available for this indicator as it was new in 2009-10. |
|||
| (A) Budget Estimate 2009-10 $’000 |
(B) Actual 2009-10 $’000 | Variation (Column B minus Column A) $’000 |
Budget Estimate 2010-11 $’000 |
|
|---|---|---|---|---|
| Program 2.1: Community Pharmacy and Pharmaceutical Awareness | ||||
| Administered Expenses | ||||
| Ordinary Annual Services (Annual Appropriation Bill 1) | 371,823 | 387,825 | 16,002 | 261,695 |
| Departmental Expenses | ||||
| Ordinary Annual Services (Annual Appropriation Bill 1) | 13,493 | 13,408 | ( 85) | 13,608 |
| Revenues from other sources | 205 | 145 | ( 60) | 214 |
| Unfunded depreciation expense1 | - | - | - | 375 |
| Operating loss / (surplus) | - | 5 | 5 | - |
| Total for Program 2.1 | 385,521 | 401,383 | 15,862 | 275,892 |
| Program 2.2: Pharmaceuticals and Pharmaceutical Services | ||||
| Administered Expenses | ||||
| Ordinary Annual Services (Annual Appropriation Bill 1) | 187,792 | 187,439 | ( 353) | 192,974 |
| Special appropriations | ||||
| National Health Act 1953 - Pharmaceutical Benefits | 8,486,519 | 8,342,035 | ( 144,484) | 9,038,627 |
| Departmental Expenses | ||||
| Ordinary Annual Services (Annual Appropriation Bill 1) | 34,332 | 34,910 | 578 | 34,624 |
| Revenues from other sources | 523 | 378 | ( 145) | 544 |
| Unfunded depreciation expense1 | - | - | - | 954 |
| Operating loss / (surplus) | - | 14 | 14 | - |
| Total for Program 2.2 | 8,709,166 | 8,564,776 | ( 144,390) | 9,267,723 |
| Program 2.3: Targeted Assistance - Pharmaceuticals | ||||
| Administered Expenses | ||||
| Ordinary Annual Services (Annual Appropriation Bill 1) | 76,152 | 79,501 | 3,349 | 119,326 |
| Departmental Expenses | ||||
| Ordinary Annual Services (Annual Appropriation Bill 1) | 1,301 | 1,477 | 176 | 1,312 |
| Revenues from other sources | 20 | 16 | ( 4) | 21 |
| Unfunded depreciation expense1 | - | - | - | 36 |
| Operating loss / (surplus) | - | 1 | 1 | - |
| Total for Program 2.3 | 77,473 | 80,995 | 3,522 | 120,695 |
| Program 2.4: Targeted Assistance - Aids and Appliances | ||||
| Administered Expenses | ||||
| Ordinary Annual Services (Annual Appropriation Bill 1) | 617 | 617 | - | 1,521 |
| Special appropriations | ||||
| National Health Act 1953 - Aids and Appliances | 230,098 | 227,182 | ( 2,916) | 248,579 |
| Departmental Expenses | ||||
| Ordinary Annual Services (Annual Appropriation Bill 1) | 2,362 | 2,784 | 422 | 2,382 |
| Revenues from other sources | 36 | 30 | ( 6) | 37 |
| Unfunded depreciation expense1 | - | - | - | 66 |
| Operating loss / (surplus) | - | 1 | 1 | - |
| Total for Program 2.4 | 233,113 | 230,614 | ( 2,499) | 252,585 |
| Outcome 2 Totals by appropriation type | ||||
| Administered Expenses | ||||
| Ordinary Annual Services (Annual Appropriation Bill 1) | 636,384 | 655,382 | 18,998 | 575,516 |
| Special appropriations | 8,716,617 | 8,569,217 | ( 147,400) | 9,287,206 |
| Departmental Expenses | ||||
| Ordinary Annual Services (Annual Appropriation Bill 1) | 51,488 | 52,579 | 1,091 | 51,926 |
| Revenues from other sources | 784 | 569 | ( 215) | 816 |
| Unfunded depreciation expense1 | - | - | - | 1,431 |
| Operating loss / (surplus) | - | 21 | 21 | - |
| Total Expenses for Outcome 2 | 9,405,273 | 9,277,768 | ( 127,505) | 9,916,895 |
| Average Staffing Level (Number) | 267 | 271 | 4 | 259 |
1 Reflects the change to net cash appropriation framework implemented from 2010-11.
Produced by the Portfolio Strategies Division, Australian
Government Department of Health and Ageing.
URL: http://www.health.gov.au/internet/annrpt/publishing.nsf/Content/annual-report-0910-toc~0910-2~0910-2-3~0910-2-3-2
If you would like to know more or give us your comments contact: annrep@health.gov.au
HOME
CONTENTS
SEARCH
PREVIOUS YEARS
Return to top of page
Print this page